检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]遵义医学院附属医院妇科,贵州遵义563003
出 处:《中华医院感染学杂志》2015年第24期5691-5693,共3页Chinese Journal of Nosocomiology
基 金:贵州省卫生厅基金资助项目(GW-2011B-039)
摘 要:目的探讨头孢孟多酯联合奥硝唑治疗妇科患者腹腔镜术后感染的治疗效果,为临床治疗提供参考依据。方法对2011年5月-2013年3月收治的64例妇科腹腔镜术后感染患者随机分为对照组与观察组,每组各32例,对照组患者采用奥硝唑治疗,观察组患者在对照组治疗的基础上加用头孢孟多酯联合治疗,比较两组患者病原菌清除率及疗效,数据采用SPSS 16.0软件进行统计分析。结果患者感染治疗总有效率观察组为87.5%、对照组为68.8%,患者病原菌清除率观察组为87.5%、对照组为73.5%,两组总有效率及清除率比较差异均有统计学意义(P<0.05)。结论采用头孢孟多酯与奥硝唑的联合抗菌治疗方案在妇科腹腔镜的细菌清除率方面有显著性的提高,在治疗妇科腹腔镜术后感染治疗有效率也有显著性的提高,因此值得对孢孟多酯与奥硝唑的联合抗菌治疗方案进行进一步的研究。OBJECTIVE To discuss the efficacy of cefamandole combined With ornidazole for treatment of nosocomial infections after gynecological taparoscopic surgery, so as to provide reference for clinical treatment. METHODS The 64 cases of infection after laparoscopic surgery admitted and treated in May 2011 to Mar. 2013 were randomly divided into the control group and the observation groups, with 32 patients in each group.' The control group received ornidazole for treatment and the observation group received combined treatment with cefamandole on the basis of the treatment in the control group. The bacterial clearance rate and the efficacy were compared between the two groups and the software SPSS 16.0 was used for statistical analysis. RESULTS The total effective rate was 87.5% for the observation group and 68.8% for the control group, the bacterial clearance rate was 87.5 % for the observation group and 73.5 % for the control group (P〈0.05). CONCLUSION The bacterial clearance rate and the efficacy were significantly improved after the combined antibacterial therapy of cefamandole and ornidazole for treatment of infection after gynecological laparoscopic surgery. It is worthy to conduct further researches on the combined antibacterial therapy of cefamandole and ornidazole.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.93